Immunotherapy, the hottest field in cancer research, seeks to supercharge the body’s natural defenses against deadly tumors. Two different approaches are driving the buzz, and one of them got a big boost in August when the Food and Drug Administration approved a “living drug” to treat acute lymphoblastic leukemia (ALL) in children and young adults who’ve stopped responding to chemotherapy. The product, dubbed tisagenlecleucel (pronounced tis-a-gen-LEK-loo-sell), is the f…